Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pien Tze Huang capsules for perioperative inflammation after unilateral primary total knee replacement
ChiCTR1800019257Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Guangzhou University of Chinese Medicine
- Start
- Oct 2018
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of Pien Tze Huang in knee osteoarthritis (OA) (2 arms), sponsored by First Affiliated Hospital of Guangzhou University of Chinese Medicine. Primary endpoint: Change from baseline in C-reactive protein at 2 weeks after total knee replacement. Planned start Oct 2018; status: not yet recruiting.
02
Drugs
Pien Tze Huang
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on ChiCTR1800019257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019257.